vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Metropolitan Bank Holding Corp. (MCB). Click either name above to swap in a different company.

Metropolitan Bank Holding Corp. is the larger business by last-quarter revenue ($88.5M vs $74.7M, roughly 1.2× Health Catalyst, Inc.). Metropolitan Bank Holding Corp. runs the higher net margin — 35.5% vs -121.9%, a 157.4% gap on every dollar of revenue. On growth, Metropolitan Bank Holding Corp. posted the faster year-over-year revenue change (25.4% vs -6.2%). Over the past eight quarters, Metropolitan Bank Holding Corp.'s revenue compounded faster (14.3% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Sandy Spring Bancorp, Inc. was a bank holding company headquartered in Olney, Maryland and operating in the Washington metropolitan area. In addition to banking services, the company offered commercial and personal lines of insurance, surety bonds, workers compensation insurance, and professional liability insurance protection as well as financial planning, wealth management, and asset management for high-net-worth individuals, businesses, and associations. In April 2025, the company was acqu...

HCAT vs MCB — Head-to-Head

Bigger by revenue
MCB
MCB
1.2× larger
MCB
$88.5M
$74.7M
HCAT
Growing faster (revenue YoY)
MCB
MCB
+31.5% gap
MCB
25.4%
-6.2%
HCAT
Higher net margin
MCB
MCB
157.4% more per $
MCB
35.5%
-121.9%
HCAT
Faster 2-yr revenue CAGR
MCB
MCB
Annualised
MCB
14.3%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
HCAT
HCAT
MCB
MCB
Revenue
$74.7M
$88.5M
Net Profit
$-91.0M
$31.4M
Gross Margin
Operating Margin
-115.3%
Net Margin
-121.9%
35.5%
Revenue YoY
-6.2%
25.4%
Net Profit YoY
-340.3%
92.2%
EPS (diluted)
$-1.29
$2.92

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
MCB
MCB
Q1 26
$88.5M
Q4 25
$74.7M
$88.4M
Q3 25
$76.3M
$79.8M
Q2 25
$80.7M
$76.3M
Q1 25
$79.4M
$70.6M
Q4 24
$79.6M
$71.0M
Q3 24
$76.4M
$71.5M
Q2 24
$75.9M
$67.7M
Net Profit
HCAT
HCAT
MCB
MCB
Q1 26
$31.4M
Q4 25
$-91.0M
$28.9M
Q3 25
$-22.2M
$7.1M
Q2 25
$-41.0M
$18.8M
Q1 25
$-23.7M
$16.4M
Q4 24
$-20.7M
$21.4M
Q3 24
$-14.7M
$12.3M
Q2 24
$-13.5M
$16.8M
Gross Margin
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Operating Margin
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
-115.3%
46.6%
Q3 25
-22.9%
12.8%
Q2 25
-46.0%
35.1%
Q1 25
-25.4%
33.1%
Q4 24
-22.0%
44.1%
Q3 24
-17.9%
24.6%
Q2 24
-20.8%
35.3%
Net Margin
HCAT
HCAT
MCB
MCB
Q1 26
35.5%
Q4 25
-121.9%
32.6%
Q3 25
-29.1%
8.9%
Q2 25
-50.8%
24.6%
Q1 25
-29.9%
23.2%
Q4 24
-26.0%
30.2%
Q3 24
-19.3%
17.2%
Q2 24
-17.8%
24.8%
EPS (diluted)
HCAT
HCAT
MCB
MCB
Q1 26
$2.92
Q4 25
$-1.29
$2.74
Q3 25
$-0.32
$0.67
Q2 25
$-0.59
$1.76
Q1 25
$-0.35
$1.45
Q4 24
$-0.33
$1.89
Q3 24
$-0.24
$1.08
Q2 24
$-0.23
$1.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
MCB
MCB
Cash + ST InvestmentsLiquidity on hand
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$948.3M
Total Assets
$502.6M
$8.8B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
$95.7M
$393.6M
Q3 25
$91.5M
$385.9M
Q2 25
$97.3M
$152.5M
Q1 25
$342.0M
$196.5M
Q4 24
$392.0M
$200.3M
Q3 24
$387.3M
$318.5M
Q2 24
$308.3M
$244.7M
Total Debt
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Stockholders' Equity
HCAT
HCAT
MCB
MCB
Q1 26
$948.3M
Q4 25
$245.8M
$743.1M
Q3 25
$331.9M
$732.0M
Q2 25
$347.5M
$723.0M
Q1 25
$376.8M
$737.8M
Q4 24
$365.2M
$729.8M
Q3 24
$355.0M
$715.2M
Q2 24
$357.0M
$692.4M
Total Assets
HCAT
HCAT
MCB
MCB
Q1 26
$8.8B
Q4 25
$502.6M
$8.3B
Q3 25
$587.1M
$8.2B
Q2 25
$616.2M
$7.9B
Q1 25
$891.5M
$7.6B
Q4 24
$858.9M
$7.3B
Q3 24
$813.0M
$7.4B
Q2 24
$691.7M
$7.3B
Debt / Equity
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
MCB
MCB
Operating Cash FlowLast quarter
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
$9.9M
$88.7M
Q3 25
$-464.0K
$31.8M
Q2 25
$-9.0M
$18.4M
Q1 25
$280.0K
$7.8M
Q4 24
$-3.5M
$148.5M
Q3 24
$6.2M
$4.8M
Q2 24
$1.6M
$35.3M
Free Cash Flow
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
FCF Margin
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Capex Intensity
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
0.5%
Q3 24
0.9%
Q2 24
0.4%
Cash Conversion
HCAT
HCAT
MCB
MCB
Q1 26
Q4 25
3.07×
Q3 25
4.47×
Q2 25
0.98×
Q1 25
0.47×
Q4 24
6.93×
Q3 24
0.39×
Q2 24
2.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

MCB
MCB

Segment breakdown not available.

Related Comparisons